Chamberlain JS - Search Results

1

Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging.

Wang Z, Storb R, Lee D, Kushmerick MJ, Chu B, Berger C, Arnett A, Allen J, Chamberlain JS, Riddell SR, Tapscott SJ. Wang Z, et al. Among authors: chamberlain js. Mol Ther. 2010 Mar;18(3):617-24. doi: 10.1038/mt.2009.294. Epub 2009 Dec 29. Mol Ther. 2010. PMID: 20040912 Free PMC article.

2

Immune evasion by muscle-specific gene expression in dystrophic muscle.

Hartigan-O'Connor D, Kirk CJ, Crawford R, Mulé JJ, Chamberlain JS. Hartigan-O'Connor D, et al. Among authors: chamberlain js. Mol Ther. 2001 Dec;4(6):525-33. doi: 10.1006/mthe.2001.0496. Mol Ther. 2001. PMID: 11735336 Free article.

3

Systemic delivery of genes to striated muscles using adeno-associated viral vectors.

Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG, Russell DW, Chamberlain JS. Gregorevic P, et al. Among authors: chamberlain js. Nat Med. 2004 Aug;10(8):828-34. doi: 10.1038/nm1085. Epub 2004 Jul 25. Nat Med. 2004. PMID: 15273747 Free PMC article.

4

Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6.

Blankinship MJ, Gregorevic P, Allen JM, Harper SQ, Harper H, Halbert CL, Miller AD, Chamberlain JS. Blankinship MJ, et al. Among authors: chamberlain js. Mol Ther. 2004 Oct;10(4):671-8. doi: 10.1016/j.ymthe.2004.07.016. Mol Ther. 2004. PMID: 15451451 Free article.

5

Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin.

Li S, Kimura E, Fall BM, Reyes M, Angello JC, Welikson R, Hauschka SD, Chamberlain JS. Li S, et al. Among authors: chamberlain js. Gene Ther. 2005 Jul;12(14):1099-108. doi: 10.1038/sj.gt.3302505. Gene Ther. 2005. PMID: 15759015

6

Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery.

Abmayr S, Gregorevic P, Allen JM, Chamberlain JS. Abmayr S, et al. Among authors: chamberlain js. Mol Ther. 2005 Sep;12(3):441-50. doi: 10.1016/j.ymthe.2005.04.001. Mol Ther. 2005. PMID: 16099410 Free article.

7

Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors.

Blankinship MJ, Gregorevic P, Chamberlain JS. Blankinship MJ, et al. Among authors: chamberlain js. Mol Ther. 2006 Feb;13(2):241-9. doi: 10.1016/j.ymthe.2005.11.001. Epub 2005 Dec 19. Mol Ther. 2006. PMID: 16361117 Free article. Review.

8

Gene therapy for Duchenne muscular dystrophy: AAV leads the way.

Judge LM, Chamberlain JS. Judge LM, et al. Among authors: chamberlain js. Acta Myol. 2005 Dec;24(3):184-93. Acta Myol. 2005. PMID: 16629052 Review.

9

rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice.

Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L, Finn E, Adams ME, Froehner SC, Murry CE, Chamberlain JS. Gregorevic P, et al. Among authors: chamberlain js. Nat Med. 2006 Jul;12(7):787-9. doi: 10.1038/nm1439. Epub 2006 Jul 2. Nat Med. 2006. PMID: 16819550 Free PMC article.

10

Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy.

Wang Z, Allen JM, Riddell SR, Gregorevic P, Storb R, Tapscott SJ, Chamberlain JS, Kuhr CS. Wang Z, et al. Among authors: chamberlain js. Hum Gene Ther. 2007 Jan;18(1):18-26. doi: 10.1089/hum.2006.093. Hum Gene Ther. 2007. PMID: 17176210

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

251 results

Search Page

Filters